| lanifibranor (IVA337) / Inventiva, Hepalys Pharma |
2020-004986-38: A clinical study to assess the long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis |
|
|
| Not yet recruiting | 3 | 2000 | Europe, RoW | Lanifibranor, IVA337, Film-coated tablet | Inventiva S.A., INVENTIVA S.A., Inventiva SA | Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Steatohepatitis (NASH), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
2021-005057-87: A clinical study to find out how safe and effective Lanifibranor is in patientswith Non-alcoholic steatohepatitis (NASH) and type 2 Diabetes.Lanifibranor will be studied when taken alone or in combination withEmpagliflozin. |
|
|
| Not yet recruiting | 2 | 63 | Europe | Lanifibranor, Jardiance, IVA337, Film-coated tablet, Coated tablet, Jardiance | Inventiva S.A., Inventiva SA | Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH), Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
NCT03459079: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 2 | 128 | US | Lanifibranor, IVA 337, Placebo | University of Florida, Inventiva Pharma | Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | 04/23 | 06/23 | | |
|
|
|
NCT06126562: A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects |
|
|
| Completed | 1 | 24 | RoW | Lanifibranor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmacokinetic | 11/23 | 12/23 | | |
